TMDX logo

TRANSMEDICS GROUP INC

TMDXNASDAQ
πŸ† #1589 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track TMDX
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$2.96B
Small Cap
πŸ“ˆRevenue Growth (YoY)
37.1%
High Growth
πŸ“ŠGross Margin
58.6%
Healthy
πŸ’΅FCF Margin
6.1%
Moderate
βš–οΈP/S Ratio
4.1x
Fair
Otter Score
76
Strong
No chart data available for TMDX.

Trading Snapshot

Day Range
β€”
52-Week Range
$60.11 – $156.00
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
34.7M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$605M
Last Q Revenue
$203M
P/E Ratio
20.3
P/S Ratio
4.1x
EPS (TTM)
$4.16
Dividend Yield
0.00%
Dilution (1yr)
+16.2%
TMDX logo

TRANSMEDICS GROUP INC

TMDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$605Mβ–² +37.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.9%β–² +0.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$109Mβ–² +189.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$134Mβ–Ό βˆ’265.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.9Mβ–² +16.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$19Mβ–² +$200M YoY
StockOtter Β· stockotter.space

About TRANSMEDICS GROUP INC

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.